Placebo effect in child and adolescent psychiatric trials

European Neuropsychopharmacology

Volumn 22, Issue 11, 2012, Pages 787-799

  Parellada, Mara ^a   Moreno, Carmen ^a   Moreno, Miguel ^a   Espliego, Ana ^a   de Portugal, Enrique ^a   Arango, Celso ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Adolescent psychiatry; Child psychiatry; Clinical trials; Placebo effect

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLMITRIPTAN;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG INDUSTRY; EFFECT SIZE; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MIGRAINE; OBSESSIVE COMPULSIVE DISORDER; PLACEBO EFFECT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SCREENING; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC);

ADOLESCENT; ADOLESCENT DEVELOPMENT; ADOLESCENT PSYCHOLOGY; CHILD; CHILD DEVELOPMENT; CHILD PSYCHOLOGY; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; NEUROGENESIS; PLACEBO EFFECT; PLACEBOS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84861627199     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.09.007     Document Type: Article

References (112)

1. Anderson I.M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 1998, 7(Suppl 1):11-17.
2. Arango C., Bobes J., Kirkpatrick B., Garcia-Garcia M., Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur. Neuropsychopharmacol. 2011.
3. Bauman D.E., Bul P.I. Human inheritability of hypnotizability. Genetika 1981, 17:352-356.
4. Berard R., Fong R., Carpenter D.J., Thomason C., Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J. Child Adolesc. Psychopharmacol. 2006, 16:59-75.
5. Birmaher B., Axelson D.A., Monk K., Kalas C., Clark D.B., Ehmann M., Bridge J., Heo J., Brent D.A. Fluoxetine for the treatment of childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42:415-423.
6. Birmaher B., Brent D.A., Kolko D., Baugher M., Bridge J., Holder D., Iyengar S., Ulloa R.E. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch. Gen. Psychiatry 2000, 57:29-36.
7. Birmaher B., Waterman G.S., Ryan N.D., Perel J., McNabb J., Balach L., Beaudry M.B., Nasr F.N., Karambelkar J., Elterich G., Quintana H., Williamson D.E., Rao U. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. J. Am. Acad. Child Adolesc. Psychiatry 1998, 37:527-535.
8. Bridge J.A., Birmaher B., Iyengar S., Barbe R.P., Brent D.A. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J. Psychiatry 2009, 166:42-49.
9. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
10. Cardena E., Alarcon A., Capafons A., Bayot A. Effects on suggestibility of a new method of active-alert hypnosis: alert hand. Int. J. Clin. Exp. Hypn. 1998, 46:280-294.
11. Center for Evidence Based Medicine Oxford Center for Evidence-based Medicine-Levels of Evidence 2009, vol. 2011. University of Oxford, Oxford.
12. Cohen D., Consoli A., Bodeau N., Purper-Ouakil D., Deniau E., Guile J.M., Donnelly C. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J. Child Adolesc. Psychopharmacol. 2010, 20:39-47.
13. Cohen D., Deniau E., Maturana A., Tanguy M.L., Bodeau N., Labelle R., Breton J.J., Guile J.M. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PLoS One 2008, 3:e2632.
14. Correll C.U., Sheridan E.M., DelBello M.P. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010, 12:116-141.
15. Curry J., Rohde P., Simons A., Silva S., Vitiello B., Kratochvil C., Reinecke M., Feeny N., Wells K., Pathak S., Weller E., Rosenberg D., Kennard B., Robins M., Ginsburg G., March J. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J. Am. Acad. Child Adolesc. Psychiatry 2006, 45:1427-1439.
16. De Pascalis V., Chiaradia C., Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 2002, 96:393-402.
17. Dekker M.C., Ferdinand R.F., van Lang N.D., Bongers I.L., van der Ende J., Verhulst F.C. Developmental trajectories of depressive symptoms from early childhood to late adolescence: gender differences and adult outcome. J. Child Psychol. Psychiatry 2007, 48:657-666.
18. DelBello M.P., Chang K., Welge J.A., Adler C.M., Rana M., Howe M., Bryan H., Vogel D., Sampang S., Delgado S.V., Sorter M., Strakowski S.M. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009, 11:483-493.
19. Dickstein D.P., Towbin K.E., Van Der Veen J.W., Rich B.A., Brotman M.A., Knopf L., Onelio L., Pine D.S., Leibenluft E. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J. Child Adolesc. Psychopharmacol. 2009, 19:61-73.
20. Dixon M., Labelle L., Laurence J.R. A multivariate approach to the prediction of hypnotic susceptibility. Int. J. Clin. Exp. Hypn. 1996, 44:250-264.
21. Emslie G.J. Understanding placebo response in pediatric depression trials. Am. J. Psychiatry 2009, 166:1-3.
22. Emslie G.J., Heiligenstein J.H., Hoog S.L., Wagner K.D., Findling R.L., McCracken J.T., Nilsson M.E., Jacobson J.G. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 2004, 43:1397-1405.
23. Emslie G.J., Heiligenstein J.H., Wagner K.D., Hoog S.L., Ernest D.E., Brown E., Nilsson M., Jacobson J.G. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41:1205-1215.
24. Emslie G.J., Kennard B.D., Mayes T.L., Nightingale-Teresi J., Carmody T., Hughes C.W., Rush A.J., Tao R., Rintelmann J.W. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am. J. Psychiatry 2008, 165:459-467.
25. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T., Rintelmann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 1997, 54:1031-1037.
26. Enserink M. Can the placebo be the cure?. Science 1999, 284:238-240.
27. European Parliment, 2006. Regulation (EC) No 1901/2006 of the European Parliment and of the Council of 12 December, Official Journal of the European Union, L378/1.
28. Evers S., Marziniak M., Frese A., Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia 2009, 29:436-444.
29. Faraone S.V., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child Adolesc. Psychiatry 2010, 19:353-364.
30. Fava M. Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 1996, 35:1292-1303.
31. Fernandes R., Ferreira J.J., Sampaio C. The placebo response in studies of acute migraine. J. Pediatr. 2008, 152:527-533. 533.e1.
32. Findling R.L., Short E.J., Manos M.J. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:1441-1447.
33. Finniss D.G., Kaptchuk T.J., Miller F., Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 375:686-695.
34. Fisher H.R., McKevitt C., Boaz A. Why do parents enrol their children in research: a narrative synthesis. J. Med. Ethics 2011.
35. Fonseca D.M., Silva C.L., Paula M.O., Soares E.G., Marchal G., Horn C., Bonato V.L. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 2007, 121:508-517.
36. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
37. Geddes J.R., Freemantle N., Mason J., Eccles M.P., Boynton J., 2005. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (Cochrane Review). In: The Cochrane Library, vol. issue 4,Update Software, Oxford.
38. Geller B., Cooper T.B., McCombs H.G., Graham D., Wells J. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacol. Bull. 1989, 25:101-108.
39. Geller D.A., Biederman J., Stewart S.E., Mullin B., Martin A., Spencer T., Faraone S.V. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am. J. Psychiatry 2003, 160:1919-1928.
40. Goldbeck L., Vitiello B. Reporting clinical trials of psychosocial interventions in child and adolescent psychiatry and mental health. Child Adolesc. Psychiatry Ment. Health 2011, 5:4.
41. Goodenough B., Addicoat L., Champion G.D., McInerney M., Young B., Juniper K., Ziegler J.B. Pain in 4- to 6-year-old children receiving intramuscular injections: a comparison of the Faces Pain Scale with other self-report and behavioral measures. Clin. J. Pain 1997, 13:60-73.
42. Goodenough B., Kampel L., Champion G.D., Laubreaux L., Nicholas M.K., Ziegler J.B., McInerney M. An investigation of the placebo effect and age-related factors in the report of needle pain from venipuncture in children. Pain 1997, 72:383-391.
43. Goodyer I., Dubicka B., Wilkinson P., Kelvin R., Roberts C., Byford S., Breen S., Ford C., Barrett B., Leech A., Rothwell J., White L., Harrington R. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007, 335:142.
44. Goodyer I.M., Dubicka B., Wilkinson P., Kelvin R., Roberts C., Byford S., Breen S., Ford C., Barrett B., Leech A., Rothwell J., White L., Harrington R. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT Trial. Health Technol. Assess. 2008, 12. iii-iv, ix-60.
45. Goodyer I.M., Wilkinson P., Dubicka B., Kelvin R. Forum: the use of selective serotonin reuptake inhibitors in depressed children and adolescents: commentary on the meta-analysis by Hetrick et al. Curr. Opin. Psychiatry 2010, 23:58-61.
46. Grelotti D.J., Kaptchuk T.J. Placebo by proxy. BMJ 2011, 343:d4345.
47. Haas M., Unis A.S., Armenteros J., Copenhaver M.D., Quiroz J.A., Kushner S.F. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol. 2009, 19:611-621.
48. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 2006, 63:332-339.
49. Harrington R., Campbell F., Shoebridge P., Whittaker J. Meta-analysis of CBT for depression in adolescents. J. Am. Acad. Child Adolesc. Psychiatry 1998, 37:1005-1007.
50. Harrington R., Whittaker J., Shoebridge P., Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998, 316:1559-1563.
51. Hazell P., O'Connell D., Robertson J., Henry D. Efficacy of Evicyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995, 310:897-901.
52. Howland R.H. Understanding the placebo effect. Part 1: Placebo use in clinical trials. J. Psychosoc. Nurs. Ment. Health Serv. 2008, 46:17-20.
53. Hrobjartsson A., Gotzsche P.C. Placebo interventions for all clinical conditions. Cochrane Database Syst. Rev. 2010, CD003974.
54. In-Albon T., Schneider S. Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother. Psychosom. 2007, 76:15-24.
55. Kahana S.Y., Youngstrom E.A., Findling R.L., Calabrese J.R. Employing parent, teacher, and youth self-report checklists in identifying pediatric bipolar spectrum disorders: an examination of diagnostic accuracy and clinical utility. J. Child Adolesc. Psychopharmacol. 2003, 13:471-488.
56. Kaptchuk T.J., Kelley J.M., Deykin A., Wayne P.M., Lasagna L.C., Epstein I.O., Kirsch I., Wechsler M.E. Do "placebo responders" exist?. Contemp. Clin. Trials 2008, 29:587-595.
57. Keller M.B., Ryan N.D., Strober M., Klein R.G., Kutcher S.P., Birmaher B., Hagino O.R., Koplewicz H., Carlson G.A., Clarke G.N., Emslie G.J., Feinberg D., Geller B., Kusumakar V., Papatheodorou G., Sack W.H., Sweeney M., Wagner K.D., Weller E.B., Winters N.C., Oakes R., McCafferty J.P. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:762-772.
58. Kemmler G., Hummer M., Widschwendter C., Fleischhacker W.W. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch. Gen. Psychiatry 2005, 62:1305-1312.
59. Khan A., Detke M., Khan S.R., Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J. Nerv. Ment. Dis. 2003, 191:211-218.
60. Khan A., Leventhal R.M., Khan S.R., Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 2002, 22:40-45.
61. King B.H., Hollander E., Sikich L., McCracken J.T., Scahill L., Bregman J.D., Donnelly C.L., Anagnostou E., Dukes K., Sullivan L., Hirtz D., Wagner A., Ritz L. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch. Gen. Psychiatry 2009, 66:583-590.
62. Kirsch I. Challenging received wisdom: antidepressants and the placebo effect. Mcgill. J. Med. 2008, 11:219-222.
63. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5:e45.
64. Klein J.B., Jacobs R.H., Reinecke M.A. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1403-1413.
65. Kovacs M., Paulauskas S., Gatsonis C., Richards C. Depressive disorders in childhood. III. A longitudinal study of comorbidity with and risk for conduct disorders. J. Affect Disord. 1988, 15:205-217.
66. Krogsboll L.T., Hrobjartsson A., Gotzsche P.C. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med. Res. Methodol. 2009, 9:1.
67. Lidow M.S., Rakic P. Scheduling of monoaminergic neurotransmitter receptor expression in the primate neocortex during postnatal development. Cereb. Cortex 1992, 2:401-416.
68. Mandoki M.W., Tapia M.R., Tapia M.A., Sumner G.S., Parker J.L. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol. Bull. 1997, 33:149-154.
69. March J., Kratochvil C., Clarke G., Beardslee W., Derivan A., Emslie G., Green E.P., Heiligenstein J., Hinshaw S., Hoagwood K., Jensen P., Lavori P., Leonard H., McNulty J., Michaels M.A., Mossholder A., Osher T., Petti T., Prentice E., Vitiello B., Wells K. AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 2004, 43:1046-1056.
70. March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., Burns B., Domino M., McNulty S., Vitiello B., Severe J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
71. March J.S., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., Burns B., Domino M., McNulty S., Vitiello B., Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch. Gen. Psychiatry 2007, 64:1132-1143.
72. March J.S., Vitiello B. Clinical messages from the Treatment for Adolescents With Depression Study (TADS). Am. J. Psychiatry 2009, 166:1118-1123.
73. Matilde Sanchez M., Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat. Med. 2006, 25:1169-1181.
74. Miller F.G., Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am. J. Bioeth. 2009, 9:39-47.
75. Moreno C., Arango C., Parellada M., Shaffer D., Bird H. Antidepressants in child and adolescent depression: where are the bugs?. Acta Psychiatr. Scand. 2007, 115:184-195.
76. Morgan A.H. The heritability of hypnotic susceptibility in twins. J Abnorm Psychol 1973, 82:55-61.
77. Munarriz R., Bennett L., Goldstein I. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 2002, 347:1890-1891. author reply 1890-1891.
78. Page R.A., Green J.P. An update on age, hypnotic suggestibility, and gender: a brief report. Am. J. Clin. Hypn. 2007, 49:283-287.
79. Peterson K., McDonagh M.S., Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 2008, 197:1-11.
80. Piccione C., Hilgard E.R., Zimbardo P.G. On the degree of stability of measured hypnotizability over a 25-year period. J. Pers. Soc. Psychol. 1989, 56:289-295.
81. Preskorn S. Outpatient Management of Depression 2009, Professional Communications, Inc., Caddo, OK. Caddo (Ed.).
82. Quitkin F.M., Rabkin J.G., Ross D., Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Arch. Gen. Psychiatry 1984, 41:782-786.
83. Raz A., Raikhel E., Anbar R.D. Placebos in medicine: knowledge, beliefs, and patterns of use. Mcgill J. Med. 2008, 11:206-211.
84. Rheims S., Cucherat M., Arzimanoglou A., Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008, 5:e166.
85. Rief W., Nestoriuc Y., Weiss S., Welzel E., Barsky A.J., Hofmann S.G. Meta-analysis of the placebo response in antidepressant trials. J. Affect Disord. 2009, 118:1-8.
86. Ryan N.D., Puig-Antich J., Ambrosini P., Rabinovich H., Robinson D., Nelson B., Iyengar S., Twomey J. The clinical picture of major depression in children and adolescents. Arch. Gen. Psychiatry 1987, 44:854-861.
87. Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment. Retard. Dev. Disabil. Res. Rev. 2005, 11:164-170.
88. Sandler A., Glesne C., Geller G. Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD. Child Care Health Dev. 2008, 34:111-120.
89. Sandler A.D., Glesne C.E., Bodfish J.W. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J. Dev. Behav. Pediatr. 2010, 31:369-375.
90. Saps M., Di Lorenzo C. Pharmacotherapy for functional gastrointestinal disorders in children. J. Pediatr. Gastroenterol. Nutr. 2009, 48(Suppl. 2):S101-103.
91. Saps M., Youssef N., Miranda A., Nurko S., Hyman P., Cocjin J., Di Lorenzo C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009, 137:1261-1269.
92. Slavin R.E. Best evidence synthesis: an intelligent alternative to meta-analysis. J. Clin. Epidemiol. 1995, 48:9-18.
93. Stoyanova-Beninska V.V., Wohlfarth T., Isaac M., Kalverdijk L.J., van den Berg H., Gispen-de Wied C. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe. Eur. Neuropsychopharmacol. 2010.
94. Sumner C.R., Haynes V.S., Teicher M.H., Newcorn J.H. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?. Postgrad. Med. 2010, 122:52-61.
95. Swanson J.M., Hinshaw S.P., Arnold L.E., Gibbons R.D., Marcus S., Hur K., Jensen P.S., Vitiello B., Abikoff H.B., Greenhill L.L., Hechtman L., Pelham W.E., Wells K.C., Conners C.K., March J.S., Elliott G.R., Epstein J.N., Hoagwood K., Hoza B., Molina B.S., Newcorn J.H., Severe J.B., Wigal T. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1003-1014.
96. Tabor E. FDA requirements for clinical studies in pediatric patients. Regulatory Focus 2009, 14:16-21.
97. Tendal B., Higgins J.P., Juni P., Hrobjartsson A., Trelle S., Nuesch E., Wandel S., Jorgensen A.W., Gesser K., Ilsoe-Kristensen S., Gotzsche P.C. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. BMJ 2009, 339:b3128.
98. Termine C., Ferri M., Balottin U. Acute treatment of migraine in children and adolescents. Funct. Neurol. 2008, 23:63-69.
99. Thompson S.G., Pocock S.J. Can meta-analyses be trusted?. Lancet 1991, 338:1127-1130.
100. Tsapakis E.M., Soldani F., Tondo L., Baldessarini R.J. Efficacy of antidepressants in juvenile depression: meta-analysis. Br. J. Psychiatry 2008, 193:10-17.
101. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2008, 18:62-73.
102. Vitiello B., Hill J.L., Elia J., Cunningham E., McLeer S.V., Behar D. P.r.n. medications in child psychiatric patients: a pilot placebo-controlled study. J. Clin. Psychiatry 1991, 52:499-501.
103. Vitiello B., Severe J.B., Greenhill L.L., Arnold L.E., Abikoff H.B., Bukstein O.G., Elliott G.R., Hechtman L., Jensen P.S., Hinshaw S.P., March J.S., Newcorn J.H., Swanson J.M., Cantwell D.P. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J. Am. Acad. Child Adolesc. Psychiatry 2001, 40:188-196.
104. von Knorring A.L., Olsson G.I., Thomsen P.H., Lemming O.M., Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J. Clin. Psychopharmacol. 2006, 26:311-315.
105. Wagner K.D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M.S., Childress A., Donnelly C., Deas D. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003, 290:1033-1041.
106. Walkup J.T., Albano A.M., Piacentini J., Birmaher B., Compton S.N., Sherrill J.T., Ginsburg G.S., Rynn M.A., McCracken J., Waslick B., Iyengar S., March J.S., Kendall P.C. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N. Engl. J. Med. 2008, 359:2753-2766.
107. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847.
108. Waschbusch D.A., Pelham W.E., Waxmonsky J., Johnston C. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?. J. Dev. Behav. Pediatr. 2009, 30:158-168.
109. Weisz J.R., McCarty C.A., Valeri S.M. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol. Bull. 2006, 132:132-149.
110. Whalley B., Hyland M.E., Kirsch I. Consistency of the placebo effect. J. Psychosom. Res. 2008, 64:537-541.
111. Wohlfarth T., Kalverdijk L., Rademaker C., Schothorst P., Minderaa R., Gispen-de Wied C. Psychopharmacology for children: from off label use to registration. Eur. Neuropsychopharmacol. 2009, 19:603-608.
112. Zuddas A., Zanni R., Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur. Neuropsychopharmacol. 2011, 21:600-620.